What is Synageva BioPharma?
Synageva BioPharma is a dedicated biopharmaceutical entity focused on the discovery, development, and commercialization of innovative therapeutic products for patients suffering from rare diseases. The company's current pipeline features protein therapeutic programs targeting rare conditions with significant unmet medical needs, with several programs in various stages of development. Notably, Synageva is preparing for the global launch of Kanuma for LAL Deficiency and is actively enrolling patients in a Phase 1/2 trial for its first-mover program, SBC-103, aimed at treating MPS IIIB. A third first-mover program, SBC-105, an enzyme replacement therapy for disorders of calcification, is currently in preclinical development. Synageva also leverages its manufacturing platform to create potentially superior treatments for other rare diseases.
How much funding has Synageva BioPharma raised?
Synageva BioPharma has raised a total of $83.1M across 3 funding rounds:
Series D
$13.1M
Series F
$45M
Series G
$25M
Series D (2005): $13.1M with participation from Fuqua Ventures and Cordova Ventures
Series F (2009): $45M led by Yasuda Enterprise Development, New Leaf Venture Partners, Tullis Funds, and Hunt BioVentures
Series G (2011): $25M supported by Hunt Ventures, Yasuda Enterprise Development, and New Leaf Venture Partners
Key Investors in Synageva BioPharma
Fuqua Ventures
Fuqua Ventures is an investment firm that likely focuses on providing capital to companies with high growth potential, particularly within the biotechnology and pharmaceutical sectors, given Synageva's focus.
Hunt Ventures
Hunt Ventures, associated with Hunt Southwest Real Estate Development, may be diversifying its investment portfolio into the life sciences sector, providing strategic capital to Synageva BioPharma.
Yasuda Enterprise Development
Yasuda Enterprise Development Co Ltd is a venture capital firm based in Japan, indicating a potential international interest and backing for Synageva's rare disease therapeutics.
What's next for Synageva BioPharma?
The recent major strategic investment positions Synageva BioPharma for accelerated progress in its clinical development and commercialization efforts. With a focus on rare diseases, the company is poised to address critical patient needs through its innovative pipeline, including Kanuma and its advanced preclinical and clinical-stage programs. This capital infusion will likely support global launch preparations, further clinical trial execution, and ongoing research and development, reinforcing Synageva's commitment to advancing therapies for underserved patient populations and solidifying its market presence in the biopharmaceutical landscape.
See full Synageva BioPharma company page
